Cargando…

Antiangiogeneic Strategies in Mesothelioma

There is a strong rationale for inhibiting angiogenesis in mesothelioma. Vascular endothelial growth factor (VEGF) is an autocrine growth factor in mesothelioma and a potent mitogen for mesothelial cells. Further, the abnormal tumor vasculature promotes raised interstitial pressure and hypoxia, whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowak, Anna K., Brosseau, Solenn, Cook, Alistair, Zalcman, Gérard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040194/ https://www.ncbi.nlm.nih.gov/pubmed/32133285 http://dx.doi.org/10.3389/fonc.2020.00126

Ejemplares similares

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Immune marker expression of irradiated mesothelioma cell lines
por: Chang, Faith, et al.
Publicado: (2022)

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
por: Pluvy, Johan, et al.
Publicado: (2019)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial
por: Kok, Peey Sei, et al.
Publicado: (2022)

AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
por: Suresh, Diwakar, et al.
Publicado: (2023)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases
por: Qu, Hui, et al.
Publicado: (2023)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Editorial: Epigenetic Modifications in Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2021)

Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors
por: Indraccolo, Stefano, et al.
Publicado: (2016)

A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma
por: Martens, Marvin, et al.
Publicado: (2022)

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
por: Suo, Jiaojiao, et al.
Publicado: (2021)

Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
por: Xuan, Tian-Tian, et al.
Publicado: (2022)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Mesothelioma Driver Genes, Ferroptosis, and Therapy
por: Felley-Bosco, Emanuela, et al.
Publicado: (2019)

Monitoring Treatment Efficacy of Antiangiogenic Therapy Combined With Hypoxia-Activated Prodrugs Online Using Functional MRI
por: Ma, Mengjie, et al.
Publicado: (2021)

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
por: Guezour, Nadia, et al.
Publicado: (2022)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
por: Pina, Marta, et al.
Publicado: (2022)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
por: Guenzi, Edouard, et al.
Publicado: (2021)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

The Future of Mesothelioma Research: Basic Science Research
por: Fear, Vanessa S., et al.
Publicado: (2019)

Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR)
por: Gill, Suki, et al.
Publicado: (2022)

Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report
por: Luo, Zhilin, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells
por: Keller, Maureen, et al.
Publicado: (2019)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
por: Oehl, Kathrin, et al.
Publicado: (2018)

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
por: Zhou, Jian-Guo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0s56sjbeqbp9p3otfv6hnf2s0p